Search results for " protocol"

showing 10 items of 1320 documents

Quantitative sensory testing: a comprehensive protocol for clinical trials.

2004

We have compiled a comprehensive QST protocol as part of the German Research Network on Neuropathic Pain (DFNS) using well established tests for nearly all aspects of somatosensation. This protocol encompasses thermal as well as mechanical testing procedures. Our rationale was to test for patterns of sensory loss (small and large nerve fiber functions) or gain (hyperalgesia, allodynia, hyperpathia), and to assess both cutaneous and deep pain sensitivity. The practicality of the QST protocol was tested in 18 healthy subjects, 21-58 years, half of them female. All subjects were tested bilaterally over face, hand and foot. We determined thermal detection and pain thresholds including a test fo…

AdultMalePain Thresholdmedicine.medical_specialtyAudiologyClinical ProtocolsThreshold of painmedicineHumansPain MeasurementClinical Trials as TopicReproducibility of ResultsSensory lossHypoesthesiaMiddle AgedAnesthesiology and Pain MedicineAllodyniaHyperalgesiaResearch DesignAnesthesiaNeuropathic painHyperalgesiaHyperpathiaBody regionFemalemedicine.symptomPsychologyEuropean journal of pain (London, England)
researchProduct

Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diag…

2019

Adult neuroblastoma is an extremely infrequent neoplasm, usually occurring in the adrenal medulla or in the paraspinal sympathetic ganglia, as its childhood counterpart. We report a very unusual case of a Schwannian stroma-poor adult neuroblastoma of inguinal location, showing aberrant expression of germ cell markers: SALL4 and OCT4. This aberrant marker expression, the unusual positivity for NKX2.2 and the very scattered (instead of diffuse strong) PHOX2B expression, complicated the initial diagnosis. In this case, the posttreatment histological evaluation revealed the neuroblastic nature of the lesion. Neuroblastoma maturation after treatment is an unusual finding in adults, and in this …

AdultMalePathologymedicine.medical_specialtymedicine.medical_treatmentInguinal CanalBiologyPathology and Forensic MedicineDiagnosis DifferentialLesionNeuroblastomaSALL4NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansIfosfamideCyclophosphamideEtoposideHomeodomain ProteinsChemotherapyExtra-AdrenalNuclear ProteinsChemoradiotherapymedicine.diseaseGerm CellsHomeobox Protein Nkx-2.2medicine.anatomical_structureVincristineAbdominal NeoplasmsDactinomycinSurgeryAnatomymedicine.symptomAdrenal medullaOctamer Transcription Factor-3Germ cellAfter treatmentTranscription FactorsInternational Journal of Surgical Pathology
researchProduct

Rationale and methods for a randomized controlled trial of a movement-to-music video program for decreasing sedentary time among mother-child pairs

2015

Measured objectively, under a quarter of adults and fewer than half of preschool children meet the criteria set in the aerobic physical activity recommendations of the Centers for Disease Control and Prevention. Moreover, adults reportedly are sedentary (seated or lying down) for most of their waking hours. Importantly, greater amounts of sedentary time on parents’ part are associated with an increased risk of more sedentary time among their children. A randomized controlled trial targeting mother-child pairs has been designed, to examine whether a movement-to-music video program may be effective in reducing sedentary time and increasing physical activity in the home environment. Mother-chi…

AdultMaleProgram evaluationmedicine.medical_specialtyMothersmotivational musicphysical activityHealth Promotionvideolaw.inventionStudy ProtocolScreen timeMovement-to-musicRandomized controlled trialQuality of lifelawSurveys and QuestionnairesIntervention (counseling)sedentary behaviormedicineHumansTerveystiede - Health care scienceChildExerciseFinlandSedentary lifestyleMotivationPhysical activityMotivational musicbusiness.industryPublic Health Environmental and Occupational HealthVideotape RecordingVideoMother-Child RelationsUnited States3. Good healthSedentary behaviorChild PreschoolCohortQuality of LifePhysical therapyFemaleBiostatisticsbusinessMusicmovement-to-musicFollow-Up StudiesProgram Evaluation
researchProduct

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomis…

2017

Summary Background Combined BRAF-MEK inhibitor therapy is the standard of care for BRAF V600 -mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAF V600 -mutant melanoma. Methods COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older and had histologically confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a B…

AdultMaleProto-Oncogene Proteins B-raf0301 basic medicineOncologymedicine.medical_specialtySkin NeoplasmsTime FactorsPhases of clinical researchYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansMolecular Targeted TherapyProgression-free survivalVemurafenibMelanomaProtein Kinase InhibitorsAgedAged 80 and overSulfonamidesPerformance statusbusiness.industryMelanomaMEK inhibitorBinimetinibMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyVemurafenibOncologyTolerabilitychemistry030220 oncology & carcinogenesisMutationBenzimidazolesFemaleCarbamatesbusinessmedicine.drugThe Lancet Oncology
researchProduct

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation …

2015

Purpose The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer) study has demonstrated 3-year disease-free survival (DFS) and 6-year overall survival (OS) benefit of adjuvant oxaliplatin in stage II to III resected colon cancer. This update presents 10-year OS and OS and DFS by mismatch repair (MMR) status and BRAF mutation. Methods Survival actualization after 10-year follow-up was performed in 2,246 patients with resected stage II to III colon cancer. We assessed MMR status and BRAF mutation in 1,008 formalin-fixed paraffin-embedded specimens. Results After a median follow-up of 9.5 years, 10-year OS rates in the bolus/…

AdultMaleProto-Oncogene Proteins B-rafOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinGlutamic AcidKaplan-Meier EstimateDNA Mismatch RepairDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineHumansStage (cooking)Infusions IntravenouseducationAgedNeoplasm Stagingeducation.field_of_studyChemotherapybusiness.industryHazard ratioValineMiddle AgedPrognosismedicine.diseasedigestive system diseasesSurgeryOxaliplatinTreatment OutcomeOncologyChemotherapy AdjuvantFluorouracilColonic NeoplasmsInjections IntravenousMutationFemaleFluorouracilbusinessAdjuvantFollow-Up Studiesmedicine.drugJournal of Clinical Oncology
researchProduct

First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomiz…

2009

Abstract Background Quality of life (QoL) has gained greater importance in the management of metastatic non-small-cell lung cancer due to the palliative nature of treatment. Docetaxel (DCT) and cisplatin (CDDP) doublet has been reported to be associated to a better QoL than the weekly vinorelbine (VNR) and CDDP regimen. Recently a newer more tolerated schedule of the VNR/CDDP regimen has been published and is widely employed in medical practice. The impact of these regimens on patients' QoL as well as symptoms control and type and grading chemo-related side-effects has been compared prospectically. Methods Patients received CDDP 75mg/m 2 plus DCT 75mg/m 2 on day 1 every weeks (arm A) or CDD…

AdultMalePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniamedicine.medical_treatmentDocetaxelNeutropeniaVinblastineVinorelbineClinical ProtocolsQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerneoplasmsAgedChemotherapybusiness.industryAnemiaVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRegimenOncologyDocetaxelDisease ProgressionQuality of LifeFemaleTaxoidsCisplatinbusinessFebrile neutropeniamedicine.drugLung Cancer
researchProduct

The effect of improvisational music therapy on the treatment of depression: protocol for a randomised controlled trial

2008

Abstract Background Music therapy is frequently offered to individuals suffering from depression. Despite the lack of research into the effects of music therapy on this population, anecdotal evidence suggests that the results are rather promising. The aim of this study is to examine whether improvisational, psychodynamically orientated music therapy in an individual setting helps reduce symptoms of depression and improve other health-related outcomes. In particular, attention will be given to mediator agents, such as musical expression and interaction in the sessions, as well as to the explanatory potential of EEG recordings in investigating emotion related music perception of individuals w…

AdultMaleResearch designPsychotherapistMusic therapyAdolescentlcsh:RC435-571PopulationContext (language use)Severity of Illness Indexbehavioral disciplines and activitieslaw.inventionStudy ProtocolRandomized controlled triallawlcsh:PsychiatryHumanseducationMusic TherapyDepression (differential diagnoses)Depressive Disorder Majoreducation.field_of_studyMusical expressionMiddle AgedhumanitiesDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthTreatment OutcomeResearch DesignFemalePsychologyPeriod (music)Clinical psychologyBMC Psychiatry
researchProduct

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group stu…

2005

Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment strategies. However, the choice and application of the criteria for a haematological CR can often become a subject of debate because of regeneration more than 5% blasts may be present at the time of response evaluation; platelet and neutrophil recovery may be incomplete and marrow cellularity can vary. This study examined the individual parameters for CR in 1250 adult patients with de novo AML treated according to three successive study protocols. Patients with < or =5% blasts showed the best overall survival (OS) and the lowest relapse risk …

AdultMaleRiskmedicine.medical_specialtyPathologyAdolescentcomplete remissionMINIMAL RESIDUAL DISEASEDIAGNOSISGastroenterologyTHERAPYDisease-Free SurvivalAMLRecurrencehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPlateletacute myeloid leukaemiaLymphocyte CountProportional Hazards ModelsrevisedHematologycriteriaProportional hazards modelbusiness.industryINDUCTIONRemission InductionCancerHematologyMiddle AgedCOLONY-STIMULATING FACTORmedicine.diseaseMinimal residual diseaseCANCERHIGH-DOSE CYTARABINELeukemiamedicine.anatomical_structureLeukemia MyeloidAcute DiseaseFemaleBone marrowbusinessBritish Journal of Haematology
researchProduct

Impact of crestal and subcrestal implant placement in peri-implant bone: a prospective comparative study

2015

Background To assess the influence of the crestal or subcrestal placement of implants upon peri-implant bone loss over 12 months of follow-up. Material and Methods Twenty-six patients with a single hopeless tooth were recruited in the Oral Surgery Unit (Valencia University, Valencia, Spain). The patients were randomized into two treatment groups: group A (implants placed at crestal level) or group B (implants placed at subcrestal level). Control visits were conducted by a trained clinician at the time of implant placement and 12 months after loading. A previously established standard protocol was used to compile general data on all patients (sex and age, implant length and diameter, and bru…

AdultMaleTime FactorsOral surgeryDentistryOdontología02 engineering and technologyPeri implant boneOsseointegration03 medical and health sciences0302 clinical medicineOsseointegrationStatistical significanceMedicineHumansProspective StudiesProspective cohort studyGeneral DentistryAgedbusiness.industryResearchDental Implantation Endosseous030206 dentistryMiddle Aged021001 nanoscience & nanotechnology:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludImplant placementOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASStandard protocolSurgeryFemaleImplantOral Surgery0210 nano-technologybusinessFollow-Up Studies
researchProduct

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

2007

Objective: We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. Methods: A total of 45 heavily pretreated metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF during the treatment with cetuximab plus weekly irinotecan. VEGF circulating levels were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. Results: Basal VEGF median levels were s…

AdultMaleVascular Endothelial Growth Factor AOncologymedicine.medical_specialtyAngiogenesisColorectal cancerCetuximabAntibodies Monoclonal HumanizedIrinotecanangiogenesiscetuximabcolorectal canceririnotecansurvivalvascular endothelial growth factorBasal (phylogenetics)chemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorGeneticsmedicineHumansProspective StudiesProspective cohort studyAgedPharmacologyCetuximabbusiness.industryAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateClinical trialVascular endothelial growth factorIrinotecanTreatment OutcomechemistryDisease ProgressionMolecular MedicineCamptothecinFemaleColorectal Neoplasmsbusinessmedicine.drugPharmacogenomics
researchProduct